« Return to News | Drug Sponsors

Covidien could be selling pharma unit

Wednesday, June 8, 2011 02:51 PM

Covidien is looking to sell its pharmaceuticals unit for as much as $4 billion, according to a source familiar with the situation, Reuters has reported.

JPMorgan Chase is advising Covidien on the matter, said the source, who declined to be named because the information was not public.

Covidien may decide to keep the drugs unit if the auction fails to generate high-enough offers, the source said.

The Mansfield, Mass.-based maker of surgical products, drugs and medical supplies had been in talks with another healthcare company for its drugs business, but those talks failed, according to a report by Bloomberg.

In April, Covidien reported a higher-than-expected second-quarter profit, helped by strong demand for its medical devices, and raised its full-year revenue growth forecast.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.